Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab

@article{Leussink2008RituximabIC,
  title={Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab},
  author={Verena Isabell Leussink and Helmar Christoph Lehmann and Gerd Meyer zu H{\"o}rste and H. P. Hartung and Olaf St{\"u}ve and Bernd C. Kieseier},
  journal={Journal of Neurology},
  year={2008},
  volume={255},
  pages={1436-1438}
}
JO N 2 95 6 II trial in relapsing-remitting MS (RRMS) [6–9]. At present, the duration of the treatment effect, its effect on progression of disability, and types of adverse events associated with this drug that may occur remain elusive [10]. We report an 18-year old righthanded Caucasian male who was diagnosed with RRMS in 2001 at the age of 12 years by a neurologist in private practice. At that time, the patient experienced 3–4 relapses per year, and treatment was initiated with interferon… 

Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report

Rituximab treatment should be considered for a patient with fulminant MS who responded well to plasmapheresis who was previously well controlled with natalizumab and continued to have worsening disease activity despite fingolimod treatment.

Bridging, switching or drug holidays – how to treat a patient who stops natalizumab?

Prospective studies are warranted, to optimize treatment strategies for RRMS patients who discontinue NAT, especially because new therapies will be available in the very near future.

Investigation of the pathophysiology of progression in multiple sclerosis: studies on cerebrospinal fluid biomarkers

Evidence is presented that increased immune activity plays a critical role in PMS for axonal damage and seemed to influence sAPP/Aβ metabolism and that biomarker levels could reflect disease activity, disability progression, or therapeutic efficacy.

[Ocrelizumab for treatment of multiple sclerosis].

The available data on the efficacy and safety of long-term B‑cell depletion in MS patients are discussed and current knowledge on the role of B‑lymphocytes in the immunopathogenesis of MS is reviewed.

Rituximab and Multiple Sclerosis

This review summarizes the available data on the role of B cell in multiple sclerosis and further reports on current knowledge on the B-cell–depleting monoclonal antibody rituximab, its mechanism of action, and its efficacy on multiple sclerosis.

Targeting B Cells to Modify MS, NMOSD, and MOGAD

This review more closely examines the clinical development of CD20 depletion and the pioneering contribution of rituximab to understand the significance of this breakthrough in the context of the current MS therapeutic armamentarium.

Autoimmune disease: A role for new anti-viral therapies?

  • D. Dreyfus
  • Biology, Medicine
    Autoimmunity reviews
  • 2011

Refractory Fulminant Acute Disseminated Encephalomyelitis (ADEM) in an Adult

An adult man with a fulminant form of ADEM unresponsive to numerous treatment modalities is described.

Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis

Language Impairment and Right Hemiparesis in a 54-Year-Old Woman

A 54-year-old woman presented to the emergency room with 3 months of slurred speech, language problems, and right hemiparesis and was diagnosed with brain abscess vs. primary or metastatic neoplasm.

References

SHOWING 1-10 OF 14 REFERENCES

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

A single course of rituximab reduced inflammatory brain lesions and clinical relapses for 48 weeks and provides evidence of B-cell involvement in the pathophysiology of relapsing-remitting multiple sclerosis.

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.

Natalizumab reduced the risk of the sustained progression of disability and the rate of clinical relapse in patients with relapsing multiple sclerosis and hold promise as an effective treatment for relapsed multiple sclerosis.

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis.

Natalizumab added to interferon beta-1a was significantly more effective in patients with relapsing multiple sclerosis, and additional research is needed to elucidate the benefits and risks of this combination treatment.

Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.

Beneficial clinical effects of rituximab in relapsing-remitting MS, mediated through modulation of humoral systemic and central nervous system intrinsic immune responses, are demonstrated.

Treatment and treatment trials in multiple sclerosis

Enhanced understanding of the immunopathological processes that underlie the disease, advances in biotechnology and development of powerful magnetic resonance imaging technologies, together with improvements in clinical trial design have led to a variety of valuable therapeutic approaches, which are currently being studied in detail.

Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.

Natalizumab therapy decreased the CSF CD4(+)/CD8(+) ratio of patients with MS to levels similar to those of human immunodeficiency virus-infected patients, which may have implications for the observation that some natalizUMab-treated Patients with MS developed progressive multifocal leukoencephalopathy.

Multiple sclerosis: a complicated picture of autoimmunity

Recent findings obtained with both animal models and patients with multiple sclerosis indicate involvement of a T helper cell with a TH-17 phenotype, in contrast to previous data indicating that T helper type 1 cells are critical.

The Immunopathology of Multiple Sclerosis: An Overview

Recent evidence is described that the spectrum of MS pathology is much broader, including demyelination in the cortex and deep gray matter nuclei, as well as diffuse injury of the normal‐appearing white matter.